Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
MarketBeat

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease

BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.

The company’s chief business officer, referred to in the transcript as BJ, said BioAge is a clinical-stage biotech founded on the idea that human aging biology can be used to identify drug targets for cardiometabolic disease. He described BGE-102 as a potential best-in-class NLRP3 inhibitor being developed for cardiovascular disease and ophthalmology.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.